- Home
- NMT vs CRVO Comparison
NMT vs CRVO Comparison
Compare NMT & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMT | CRVO |
|---|---|---|
| Founded | 1993 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.8M | 47.7M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | NMT | CRVO |
|---|---|---|
| Price | $11.98 | $4.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $21.50 |
| AVG Volume (30 Days) | 15.2K | ★ 97.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.21% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,737,974.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 36.29 |
| 52 Week Low | $10.90 | $3.58 |
| 52 Week High | $12.33 | $16.50 |
Technical Indicators
Market Signals| Indicator | NMT | CRVO |
|---|---|---|
| Relative Strength Index (RSI) | 70.12 | 44.03 |
| Support Level | $11.43 | $3.58 |
| Resistance Level | $12.20 | $5.44 |
| Average True Range (ATR) | 0.08 | 0.49 |
| MACD | 0.01 | 0.12 |
| Stochastic Oscillator | 75.68 | 51.80 |
Price Performance
Historical ComparisonAbout NMT Nuveen Massachusetts Quality Municipal Income Fund
Nuveen Massachusetts Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's objective seeks to provide current income exempt from both regular federal and Massachusetts income taxes and to enhance portfolio value relative to the Massachusetts municipal bond market by investing in tax-exempt Massachusetts municipal obligations that are underrated or undervalued or that represent municipal market sectors that are undervalued.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.